Eribulin mesylate-induced c-Fos upregulation enhances cell survival in breast cancer cell lines
- 1 May 2020
- journal article
- research article
- Published by Elsevier in Biochemical and Biophysical Research Communications
- Vol. 526 (1) , 154-157
Abstract
No abstract availableKeywords
Funding Information
- Taiho Pharmaceutical Co.
- Taiho Pharmaceutical Co.
- Taiho Pharmaceutical Co.
- JSPS KAKENHI (JP19K07665)
This publication has 9 references indexed in Scilit:
- In silico analysis‐based identification of the target residue of integrin α6 for metastasis inhibition of basal‐like breast cancerGenes to Cells, 2019
- Eribulin penetrates brain tumor tissue and prolongs survival of mice harboring intracerebral glioblastoma xenograftsCancer Science, 2019
- Perspectives on The Mechanism of Action and Clinical Application of Eribulin for Metastatic Breast CancerFuture Oncology, 2019
- Multiple modes of action of eribulin mesylate: Emerging data and clinical implicationsCancer Treatment Reviews, 2018
- Triple-negative breast cancer: challenges and opportunities of a heterogeneous diseaseNature Reviews Clinical Oncology, 2016
- Eribulin Mesylate: Mechanism of Action of a Unique Microtubule-Targeting AgentClinical Cancer Research, 2015
- Eribulin mesylate reduces tumor microenvironment abnormality by vascular remodeling in preclinical human breast cancer modelsCancer Science, 2014
- Small Molecule Inhibitors Targeting Activator Protein 1 (AP-1)Journal of Medicinal Chemistry, 2014
- Eribulin mesilate suppresses experimental metastasis of breast cancer cells by reversing phenotype from epithelial–mesenchymal transition (EMT) to mesenchymal–epithelial transition (MET) statesBritish Journal of Cancer, 2014